COMMENT ON: PATHOPHYSIOLOGICAL EXPLANATION OF CARDIOVASCULAR BENEFITS OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS BY NEUROTROPHIC THEORY. MEDICAL HYPOTHESES102 (2017) 61-64-Reference-Cited by-同舟云学术

COMMENT ON: PATHOPHYSIOLOGICAL EXPLANATION OF CARDIOVASCULAR BENEFITS OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS BY NEUROTROPHIC THEORY. MEDICAL HYPOTHESES102 (2017) 61-64

Published:2022-12-01 Issue: Volume: Page:19-19
ISSN:
Container-title:INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH
language:en
Short-container-title:ijsr

Author:

G. Hristova Mariyana¹

Affiliation:

1. MD, PhD

Abstract

In connection with the published hypothesis about cardiovascular benets of sodium - glucose cotransporter - 2 inhibitors, I present my own results from treatment with Empagliphlozin 10 mg added to Metformin 2x1000 mg in a small group of patients with type 2 diabetes mellitus and metabolic syndrome [1].

Publisher

World Wide Journals

Subject

Visual Arts and Performing Arts,Communication,Energy Engineering and Power Technology,Renewable Energy, Sustainability and the Environment,Electrical and Electronic Engineering,Computer Science Applications,Mechanical Engineering,Transportation,Cardiology and Cardiovascular Medicine,Molecular Biology,Molecular Biology,Structural Biology,Catalysis,General Engineering,Physical and Theoretical Chemistry,Process Chemistry and Technology,Catalysis,Process Chemistry and Technology,Biochemistry,Bioengineering,Catalysis,Cell Biology,Genetics,Molecular Biology,General Medicine

Reference5 articles.

1. M.G. Hristova, Pathophysiological explanation of cardiovascular benefits of sodium-glucose cotransporter-2 inhibitors by neurotrophic theory, Med. Hypotheses 102 (2017) 61-64. https://doi.org/10.1016/j.mehy.2017.02.021

2. M. Packer, J. Anker, G. Butler at al, Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure, New Engl. J. Med. (2020) 1-12. https://doi.org/10.1056/NEJMoa2022190 .

3. M.G. Hristova, Metabolic syndrome-from the neurotrophic hypothesis, to a theory, Med. Hypotheses 81(2013) 627- 634. https://doi.org/10.1016/j.mehy.2013.07.018 .

4. G. Chaldakov, M. Fiore, M. Hristova et al., Neurotrophin presence in human coronary atherosclerosis and metabolic syndrome: a role for NGF and BDNF in cardiovascular disease, Prog. Brain Res. 146 (2004) 279-89. https://doi.org/10.1016/S0079-6123(03)46018-4 .

5. F. Bonnet, A. Scheen, Effects of SGLT2 inhibitors on systemic and tissue low – grade inflammation: the potential contribution to diabetes complications and cardiovascular disease, J. Diabetes Metab., 44 (2018) 457 – 464. https://doi.org/10.1016/j.diabet.2018.09.005 .